» Articles » PMID: 38675791

Nanocapsules Comprised of Purified Protein: Construction and Applications in Vaccine Research

Abstract

Nanoparticles show great promise as a platform for developing vaccines for the prevention of infectious disease. We have been investigating a method whereby nanocapsules can be formulated from protein, such that the final capsules contain only the cross-linked protein itself. Such nanocapsules are made using a silica templating system and can be customised in terms of size and porosity. Here we compare the construction and characteristics of nanocapsules from four different proteins: one a model protein (ovalbumin) and three from infectious disease pathogens, namely the influenza virus, and HIV. Two of the nanocapsules were assessed further. We confirm that nanocapsules constructed from the urease A subunit of can reduce subsequent infection in a vaccinated mouse model. Further, we show that capsules constructed from the HIV gp120 protein can be taken up by dendritic cells in tissue culture and can be recognised by antibodies raised against the virus. These results point to the utility of this method in constructing protein-only nanocapsules from proteins of varying sizes and isoelectric points.

Citing Articles

Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.

Bikorimana J, Farah R, Abusarah J, Mandl G, Erregragui M, Goncalves M iScience. 2025; 28(3):111957.

PMID: 40060894 PMC: 11889607. DOI: 10.1016/j.isci.2025.111957.


Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response.

Ning W, Yan S, Song Y, Xu H, Zhang J, Wang X Front Immunol. 2025; 15():1504124.

PMID: 39840069 PMC: 11747419. DOI: 10.3389/fimmu.2024.1504124.

References
1.
Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N . Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70(2):1100-8. PMC: 189917. DOI: 10.1128/JVI.70.2.1100-1108.1996. View

2.
Wang E, Sarmadi M, Ying B, Jaklenec A, Langer R . Recent advances in nano- and micro-scale carrier systems for controlled delivery of vaccines. Biomaterials. 2023; 303:122345. DOI: 10.1016/j.biomaterials.2023.122345. View

3.
Taki A, Smooker P . Small Wonders-The Use of Nanoparticles for Delivering Antigen. Vaccines (Basel). 2015; 3(3):638-61. PMC: 4586471. DOI: 10.3390/vaccines3030638. View

4.
Becher D, Deutscher M, Simpfendorfer K, Wijburg O, Pederson J, Lew A . Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice. Eur J Immunol. 2010; 40(10):2778-90. DOI: 10.1002/eji.200940219. View

5.
Ding Y, Li Z, Jaklenec A, Hu Q . Vaccine delivery systems toward lymph nodes. Adv Drug Deliv Rev. 2021; 179:113914. PMC: 9418125. DOI: 10.1016/j.addr.2021.113914. View